MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-15-2023
Novan ROCE Ratio 2011-2026 | NOVN
Annual ROCE Ratio Novan
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -743.32 | -163.3 | -68.62 | -189.46 | -165.08 | -284.56 | -153.02 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -68.62 | -743.32 | -252.48 |
Quarterly ROCE Ratio Novan
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 131.44 | -437.53 | -462.29 | -342.02 | -296.2 | -1021.29 | -1303.42 | -1560.79 | -1810.82 | -762.58 | -735.67 | -410.59 | -101.04 | 137.72 | 56.24 | -147.24 | -341.66 | -536.44 | -18.65 | 554.93 | 1271.45 | 2086.01 | 1580.49 | 1111.17 | 493.65 | -192.58 | -133.47 | -67.84 | -10.11 | 26.18 | 9.36 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2086.01 | -1810.82 | -104.31 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-23.06 | - | 1052.0 % | $ 415 M |  USA |
 |
Verastem
VSTM
|
-297.44 | $ 5.04 | -4.73 % | $ 349 M | USA |
 |
Voyager Therapeutics
VYGR
|
-67.24 | $ 3.96 | -4.12 % | $ 232 M | USA |
 |
VistaGen Therapeutics
VTGN
|
-79.52 | $ 0.57 | -5.87 % | $ 17.6 M | USA |
 |
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
64924.32 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-28.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
-70.32 | - | -0.23 % | $ 916 M | USA |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M | France |
 |
Aileron Therapeutics
ALRN
|
-299.27 | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
-163.42 | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-92.73 | - | -6.81 % | $ 3.04 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
-403.4 | - | -52.27 % | $ 4.45 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
-34.9 | - | -11.76 % | $ 5.79 M | USA |
 |
Acorda Therapeutics
ACOR
|
167.74 | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
-125.56 | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
-25.04 | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
-30.68 | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-196.79 | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
146.85 | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-26.11 | $ 12.41 | -11.1 % | $ 1.88 B | USA |
 |
Wave Life Sciences Ltd.
WVE
|
-40.22 | $ 6.37 | 2.66 % | $ 1.07 B |  Singapore |
 |
Xenetic Biosciences
XBIO
|
-38.33 | $ 2.72 | -2.86 % | $ 4.63 M | USA |
 |
XBiotech
XBIT
|
-39.68 | $ 2.27 | -1.73 % | $ 69.2 M | USA |
 |
Xenon Pharmaceuticals
XENE
|
-37.0 | $ 54.48 | -1.89 % | $ 4.24 B | Canada |
 |
Xeris Pharmaceuticals
XERS
|
181.87 | $ 5.4 | -3.05 % | $ 866 M | USA |
 |
X4 Pharmaceuticals
XFOR
|
-46.64 | $ 4.04 | -6.26 % | $ 171 M | USA |
 |
Xencor
XNCR
|
-27.93 | $ 11.42 | -7.23 % | $ 848 M | USA |
 |
XOMA Corporation
XOMA
|
13.56 | $ 30.17 | -1.18 % | $ 364 M | USA |
 |
BeiGene, Ltd.
BGNE
|
7.03 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
22nd Century Group
XXII
|
-73.4 | $ 2.41 | -18.03 % | $ 444 K | USA |
 |
BioDelivery Sciences International
BDSI
|
19.77 | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
-212.83 | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-45.41 | - | - | $ 3.74 B | USA |
 |
Zai Lab Limited
ZLAB
|
-32.07 | $ 18.0 | 2.8 % | $ 19.7 B |  China |
|
Enlivex Therapeutics Ltd.
ENLV
|
-66.51 | $ 1.05 | -3.67 % | $ 21.5 M | Israel |
 |
Enochian Biosciences
ENOB
|
903.05 | - | - | $ 40.5 M | USA |